Press Release / Media Release
Dear Sirs, Sub: Glenmark Pharmaceuticals receives ANDA approval for Triamcinolone Acetonide Ointment USP, 0.1% With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Fixes Book Closure for Dividend & AGM
Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 22, 2017 to September 29, 2017 (both days inclusive) for the purpose of Payment of Dividend & 39th Annual General Meeting (AGM) of the Company to be held on September 29, 2017.The dividend, if approved by the Members at the ensuing AGM, will be paid on or after October 03, 2017. Risk-reward favourable for Glenmark
Growth momentum to continue in FY18 as firm beats peers in Q1, out-licensing deal a trigger 39Th Annual General Meeting - September 29, 2017
We have to inform you that the 39th Annual General Meeting (AGM) of Members of the Company is scheduled to be held on Friday, September, 29, 2017 at 11.00 a.m. at Sunville Banquets & Conference Hall, 3rd floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018. The copy of the notice will be sent to you in due course. Pursuant to the Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, notice is hereby... Glenmark gets USFDA nod anti-herpes drug
Glenmark Pharmaceuticals has received final approval from the US health regulator for Acyclovir Ointment used for the treatment of herpes virus. Glenmark Pharmaceuticals, USA, has been granted... Press Release
Sub: Glenmark Pharmaceuticals receives ANDA approval for Acyclovir Ointment USP, 5% With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Press Release
Sub: Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis GBR 830 is an Investigational, First-in-Class, Anti-OX40 Monoclonal Antibody With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record. Glenmark Pharma Q1 net up 47% at Rs 333 cr on sales growth
Glenmark posted 47 per cent increase in consolidated net profit in Q1 FY 18 on the back of growth in sales in domestic and US markets. Net profit for the period was Rs 333 crore as against Rs 226 crore for same period last year.Overall revenue rose around 20 per cent to Rs 2363 crore led by growth in US and domestic market sales. While other companies have seen their domestic sales fall due to good and service tax related de-stocking in June, Glenmark reported 15 per cent growth in its India sales.Glenmark had seen a modest 6.8 per cent growth in domestic sales in January-March quarter. Growth was strong in April-May with some of the sales from preceding quarter materialising in the two months. Glenmark also has a strong portfolio of cardiac and anti diabetes drugs which were relatively less impacted due to destocking in June.The domestic and US business accounts for around 70 per cent of its consolidated revenue. The US sales have been boosted due to generic version of anti... Outcome of Board Meeting
Sub:- Employee Stock Options Scheme, 2016 We have to inform you that on the recommendation of the Nomination & Remuneration Committee of the Company, the Board at its meeting held on July 27, 2017, has decided to amend the Employee Stock Options Scheme, 2016, in compliance with the applicable Regulations, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. The above is for your information and record. Updates
Dear Sirs, Sub:- Employee Stock Options Scheme, 2003 We have to inform you that the Nomination & Remuneration Committee of the Company at its meeting held on July 27, 2017, has cancelled 47,000 stock options which were granted, vested but have not been exercised and have consequently elapsed, as per the terms of the Employee Stock Options Scheme, 2003. Upon Cancellation, no stock options are outstanding pursuant to Employee Stock Options Scheme, 2003....